Oscotec Inc.

Translating science into medicine
Sign Up
  1. Oscotec/ADEL Initiates First-in-Human Dosing in Ph1 of Anti-MTBR Tau Antibody ADEL-Y01 In Alzheimer's Disease

    Date2024-02-23 Mediayahoo! finance PipelineOscotec
    Read More
  2. Oscotec/ADEL Announce FDA Clearance of IND Application of ADEL-Y01 for the Treatment of Alzheimer's Disease

    Date2023-09-14 MediaBiospace PipelineOscotec
    Read More
  3. Other news to note for March 2, 2021

    Date2021-03-02 MediaBioWorld PipelineOscotec
    Read More
  4. Oscotec and Beactica Therapeutics announce license and collaboration agreement to develop new cancer drug

    Date2021-03-02 MediaCISION PipelineOscotec
    Read More
  5. Janssen Announces Phase 1 Results for Bispecific Antibody Amivantamab in the treatment of Patients with Advanced Non-Small Cell Lung Cancer Harboring Exon 20 Insertion Mutations

    Date2020-05-18 MediaBioSpace PipelineLazertinib
    Read More
  6. Lazertinib Shows Promising Antitumor Activity in Patients With EGFR+ NSCLC

    Date2019-12-14 MediaTargeted Oncology PipelineLazertinib
    Read More
  7. Yuhan to start phase-3 trial on lung cancer drug Lazertinib

    Date2019-12-12 MediaKBR (; Korea Biomedical Review) PipelineLazertinib
    Read More
  8. "Global Immune Thrombocytopenia (ITP) Market Insights, Epidemiology, and Forecasts, 2017-2028 : Focus on United States, Germany, Spain, Italy, France, and the United Kingdom, and Japan"

    Date2019-12-02 MediaPRNewswire PipelineGenosco
    Read More
  9. AXL receptor tyrosine kinase as a promising anti-cancer approach: functions, molecular mechanisms and clinical applications

    Date2019-11-04 MediaMolecular Cancer PipelineSKI-G-801
    Read More
  10. Lazertinib in patients with EGFR mutation-positive advanced non-small-cell lung cancer: results from the dose escalation and dose expansion parts of a first-in-human, open-label, multicentre, phase 1-2 study

    Date2019-11-04 MediaTHE LANCET ONCOLOGY PipelineLazertinib
    Read More
  11. Abstract 2010 : SKI-G-801, an AXL kinase inhibitor, blocks metastasis and induces anti-tumor immune response in various syngeneic cancer models

    Date2019-07-01 MediaCANCER RESEARCH PipelineSKI-G-801
    Read More
  12. Oscotec wins exception policy for continued R&D for new drugs

    Date2019-06-25 MediaKBR (; Korea Biomedical Review) PipelineOscotec
    Read More
Board Pagination Prev 1 2 3 Next
/ 3
© k2s0o1d6e0s8i2g7n. ALL RIGHTS RESERVED.
Requesting to the server, please wait.